Skip to main content

Advertisement

SpringerLink
Log in

Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Adjuvant trastuzumab (T) significantly reduces the risk of progression and death in HER-2 positive high-risk early breast cancer. The differential benefit of T, administered either sequential or concomitant, has been calculated with 2 comparative meta-analyses of randomized trials. We have meta-analyzed sequential and concomitant arms of 6 T adjuvant trials separately and then calculated the pooled hazard ratios (HRs) for disease-free survival (DFS) and overall survival (OS) in both meta-analyses. Primary cardiac event rates have also been meta-analyzed. In the concomitant T meta-analysis, HRs for DFS and OS were 0.62 and 0.68, respectively (P < 0.0001 and <0.00001 for both endpoints). Conversely, in the sequential T meta-analysis, HRs for DFS and OS were, respectively, 0.74 and 0.87, where P is, however, significant only in the first comparison (P < 0.00001 and P = 0.09). Relative risks (RRs) for major cardiac events (severe cardiac hearth failure or death) are 2.44 (P = 0.07) in the concomitant T meta-analysis and 8.35 (P < 0.0001) in the sequential T meta-analysis. Concomitant adjuvant T therapy seems to give a significant and greater benefit than sequential administration in both DFS and OS, and the number of cases of severe cardiotoxicity does not seem to be higher in concomitant administration than in the sequential one.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Perez, EA, Suman, VJ, Davidson, NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 Weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 2009;69:(abstr 80).

  2. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831, NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (abstract). J Clin Oncol. 2007;25:6s.

    Article  Google Scholar 

  3. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Cancer Res. 2009;69:500s. abstr 62.

    Google Scholar 

  4. Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27(36):6129–34.

    Article  PubMed  CAS  Google Scholar 

  5. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27(34):5685–92.

    Article  PubMed  CAS  Google Scholar 

  6. Gianni L, Goldhirsch A, Gelber RD, et al. Update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer. Breast. 2009;18(Supplement 1):S11. Abstr S25.

    Article  Google Scholar 

  7. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin, cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811.

    Article  PubMed  CAS  Google Scholar 

  8. Rastogi P, Jeong J, Geyer CE, et al. Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)-paclitaxel compared to AC-T with trastuzumab (abstract). J Clin Oncol. 2007;25:6s.

    Article  Google Scholar 

  9. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231–8.

    Article  PubMed  CAS  Google Scholar 

  10. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab, paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype, gene amplification. J Clin Oncol. 2001;19:2587.

    PubMed  CAS  Google Scholar 

  11. Gori S, Colozza M, Mosconi AM, et al. Phase II study of weekly paclitaxel, trastuzumab in anthracycline-and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer. 2004;90:36.

    Article  PubMed  CAS  Google Scholar 

  12. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab, vinorelbine or taxane study. Cancer. 2007;110:965.

    Article  PubMed  CAS  Google Scholar 

  13. Vogel CL, Tan-Chiu E. Trastuzumab plus chemotherapy: convincing survival benefit or not? J Clin Oncol. 2005;23:4247.

    Article  PubMed  CAS  Google Scholar 

  14. Esteva FJ, Valero V, Booser D, et al. Phase IIstudy of weekly docetaxel, trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800.

    Article  PubMed  CAS  Google Scholar 

  15. Montemurro F, Choa G, Faggiuolo R, et al. Safety, activity of docetaxel, trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. Am J Clin Oncol. 2003;26:95.

    PubMed  CAS  Google Scholar 

  16. Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in her-2 3+ overexpressing, fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase ii trial. J Clin Oncol. 2004;22:1071.

    Article  PubMed  CAS  Google Scholar 

  17. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase ii trial of the efficacy, safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265.

    Article  PubMed  CAS  Google Scholar 

  18. Raff JP, Rajdev L, Malik U, et al. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer. 2004;4:420.

    Article  PubMed  CAS  Google Scholar 

  19. Bontenbal M, Seynaeve C, Stouthard J et al. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastzumab/docetaxel as first-line chemotherapy in Her2-neu positive, metastatic breast cancer (HERTAX study) (Abstract). J Clin Oncol 2008;26:44s. (Abstract available online at www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34668, Accessed 17 July 2008).

  20. Inoue K, Nakagami K, Mizutani M, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat. 2010;119:127.

    Article  PubMed  CAS  Google Scholar 

  21. De Laurentiis M, Cancello G, D’Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44.

    Article  PubMed  Google Scholar 

  22. Pegram MD, Konecny GE, O’Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96:739.

    Article  PubMed  CAS  Google Scholar 

  23. Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification, response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004;96:1141.

    Article  PubMed  CAS  Google Scholar 

  24. Di Leo A, Chan S, Paesmans M, et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat. 2004;86:197.

    Article  PubMed  CAS  Google Scholar 

  25. Muller V, Witzel I, Luck HJ, et al. Prognostic, predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat. 2004;86:9.

    Article  PubMed  Google Scholar 

  26. Sjostrom J, Collan J, von Boguslawski K, et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate, 5-fluorouracil in advanced breast cancer. Eur J Cancer. 2002;38:535.

    Article  PubMed  CAS  Google Scholar 

  27. Hayes DF, Thor AD, Dressler LG, et al. HER2, response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357:1496.

    Article  PubMed  CAS  Google Scholar 

  28. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson cancer center experience. J Clin Oncol. 2006;24:4107.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, BG, Italy

    Fausto Petrelli & Sandro Barni

Authors
  1. Fausto Petrelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandro Barni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fausto Petrelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petrelli, F., Barni, S. Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med Oncol 29, 503–510 (2012). https://doi.org/10.1007/s12032-011-9897-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9897-9

Keywords

Search

Navigation